How GlaxoSmithKline plc & SkyePharma PLC Can Turbocharge Your Returns

GlaxoSmithKline plc (LON: GSK) and SkyePharma PLC (LON: SKP) can really boost your returns, but both in different ways.

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

On the face of it, GlaxoSmithKline (LSE: GSK) looks like the perfect investment. The company is one of the world’s largest pharmaceutical groups, which owns a vast consumer products business, highly profitable vaccines business and pharmaceuticals division.

However, Glaxo is faced with losing US market exclusivity on its best-selling asthma drug Advair this year, along with the additional patent on the Diskus inhaler used to deliver the drug, which has so far kept competitors at bay. Two years ago sales of this drug were responsible for almost a fifth of Glaxo’s sales but last year Advair sales as a percentage of overall group sales declined 13%.

The loss of patent protection on Advair could be described as Glaxo’s Achilles heel but the average investor can negotiate around this structural shift in the company’s business model by diversifying.

And one of the best companies to buy alongside Glaxo in a portfolio is SkyePharma (LSE: SKP).

A profitable merger

Skye has recently agreed to merge with peer Vectura, to create a new UK champion in respiratory medicines. Vectura is also developing its own generic version of Advair in partnership with Roxane Labs, a US manufacturer being acquired by UK-listed Hikma. Skye and Vectura both specialise in the formulation and delivery of inhalable respiratory drugs, working in partnership with bigger groups including Glaxo and Novartis.

All in all, this deal will generate some impressive returns for investors. Vectura predicts the deal would be earnings-enhancing in its first year, with projected annual pre-tax synergies of £10m by 2018. It’s Vectura that’s leading the deal here. Under the terms of the deal, Skye’s shareholders are set to receive 2.7977 new Vectura shares for each Skye share, valuing the latter at 449.89p each – a small premium to today’s price.

Current outlook 

Current City figures are calling for Vectura to report earnings per share of 5.1p for the year ending 31 March 2016, which means that the group’s shares are trading at a forward PE of 28.9. However, analysts have pencilled in total earnings per share growth of more than 100% for the next two years to 10.8p per share, and these forecasts could be revised significantly higher if the deal with Skye goes to plan and integration is successful. Shares in Skye trade at a forward P/E of 22.2.

Skye and Vectura are an excellent hedge against Glaxo’s patented expiry but both companies are relatively expensive and neither offer a dividend for investors. Meanwhile, Glaxo’s shares support a dividend yield of 5.9% and trade at a forward P/E of 16.2. Management has made a commitment to maintain the payout at 80p per share for the next few years.

The bottom line 

So overall, Glaxo is an excellent income investment for any portfolio, and the company is set to return to growth over the next two years. Still, some investors are concerned about Glaxo’s patent cliff and the best way to hedge against this risk is to diversify into Skye, a company that is currently in the process of being bought out for a small premium and specialises in the market where Glaxo is set to lose market share.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns shares of GlaxoSmithKline. The Motley Fool UK has recommended GlaxoSmithKline. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

How I’d use an empty Stocks and Shares ISA to aim for a £1,000 monthly passive income

Here's how using a Stocks and Shares ISA really could help those of us who plan to invest for an…

Read more »

Investing Articles

This FTSE stock is up 20% and set for its best day ever! Time to buy?

This Fool takes a look at the half-year results from Burberry (LON:BRBY) to see if the struggling FTSE stock might…

Read more »

Investing Articles

This latest FTSE 100 dip could be an unmissable opportunity to pick up cut-price stocks

The FTSE 100 has pulled back with the government’s policy choices creating some negative sentiment. But this gives us a…

Read more »

A young woman sitting on a couch looking at a book in a quiet library space.
Investing Articles

As the WH Smith share price falls 4% on annual results, is it still worth considering?

WH Smith took a hit after this morning’s results left shareholders unimpressed. With the share price down 4%, Mark Hartley…

Read more »

Investing Articles

The Aviva share price just jumped 4.5% but still yields 7.02%! Time to buy?

A positive set of results has put fresh life into the Aviva share price. Harvey Jones says it offers bags…

Read more »

Investing Articles

Can a €500m buyback kickstart the Vodafone share price?

The Vodafone share price has been a loser for investors in recent years, and the dividend has been cut. We…

Read more »

Frustrated young white male looking disconsolate while sat on his sofa holding a beer
Growth Shares

3 mistakes I now avoid when choosing which growth stocks to buy

Jon Smith runs through some of the lessons he's learnt the hard way over the years about what to look…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Should I follow Warren Buffett and sell my favourite shares?

Billionaire US investor Warren Buffett has been selling tons of Apple shares and other stocks of businesses he thinks are…

Read more »